Surfin Meta Digital Technology Pte Ltd (“Surfin”) Welcomes John Quelch and John Fennell to its Board of Directors
14.4.2023 05:00:00 EEST | Business Wire | Press release
Surfin group of companies (“Surfin Group”), headquartered in Singapore, a leading provider of digital financial solutions for under-serviced clients in emerging markets, is pleased to announce the appointments of John Quelch and John Fennell to its Board of Directors. These two highly experienced professionals bring an extensive wealth of expertise in marketing, global business strategy, risk management, and leadership to the Surfin Group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230413005053/en/
Dr. Quelch is a highly respected expert in international strategy, global marketing, and ESG with more than five decades of experience serving as a non-executive director of public companies in the USA and UK. As a member of Surfin’s board of directors, Quelch brings a wealth of experience in corporate governance, strategic planning, and ESG initiatives. He has served on the boards of several important public companies, including Alere, Aramark, Gentiva Health Services, Pepsi Bottling Group, and WPP. He has also served as Dean of both the China Europe International Business School and London Business School. "I am excited to join Surfin Group's board of directors and to work with the company's talented leadership team," said Quelch. "Surfin Group is at the forefront of providing inclusive finance through its innovative digital solutions to emerging markets, and I look forward to contributing my expertise to support the company's growth and success." Quelch was awarded the CBE (Commander of the Order of the British Empire).
John Fennell, a seasoned risk management professional, will bolster Surfin Group's efforts to optimize its risk and control environment as the company looks to expand its digital financial technology offerings, including robo-advisor wealth management and digital security trading for Millennials and Gen Z in developing countries. Mr. Fennell has previously served as Chief Risk Officer of the Options Clearing Corporation, overseeing risk at multiple organizations responsible for systemic resilience of financial markets. His participation in serving on the committees of World Federation of Exchanges and CCP12 will prove invaluable as the company seeks to develop cross-border trading products and engage with local exchanges. Fennell shared his thoughts on the appointment, saying, "I'm thrilled to be part of Surfin Group's mission to promote financial inclusion and innovation in developing countries. I look forward to applying my risk management expertise to ensure the company's continued success and growth."
Yanan Wu, CFA, Ph.D, Chairman of Surfin Group, expressed the company's enthusiasm about the appointments of Dr. Quelch and Mr. Fennell: "We are thrilled to welcome both John Quelch and John Fennell to our Board of Directors. We are confident that their combined expertise and experience will significantly contribute to our growth and help us achieve our ambitions of becoming a forefront leader in digital financial technologies, promoting transparency, innovation, and financial inclusion in developing countries."
About Surfin Group
Surfin Group, headquartered in Singapore, is a leading provider of digital financial solutions for under-serviced clients in emerging markets. The group is committed to providing innovative digital solutions to its clients, with a focus on transparency, inclusion, innovation, and compassion. For more information, please visit www.surfin.sg.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005053/en/
Contact information
Media:
Daju Gu, Board Secretary
Email: daju.gu@surfin.sg
Phone: +1 416 414 3426
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
